Employees: 5,019
Size Lumexa Imaging (LMRI) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.35B, the 2045th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.01 on 18 Nov 2026.
Performance Over six months the shares gained 89.3%, against +14.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 7.8% over the last twelve months (peer median +6.9%); the operating margin is 2.2% (peer median 6.2%).
Valuation It trades at 16.0× forward earnings against a peer median of 29.4× (5th cheapest of 16).
Capital Return on invested capital runs 7.0 points below its cost of capital (8.2% WACC).
Short interest Short interest is 1.9% of the free float (30 Oct 2026).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $1.06B | $1.02B | $949M | $936M |
| Revenue growth | — | +8% | +1% | — |
| Gross profit | $120M | $117M | $54.1M | $42.3M |
| EBITDA | $83.2M | $82.6M | $40.9M | $59.2M |
| Net income | -$17.1M | -$47.1M | -$94.1M | -$122M |
| Free cash flow | n/a | -$6.40M | $13.0M | $13.5M |
| Capital expenditure | n/a | $23.5M | $27.8M | $24.0M |
| Total debt | $977M | $963M | $1.31B | $1.30B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LMRI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +31.2% | -1.6% | highest of 21 |
| 6-month return | +89.3% | +14.4% | highest of 21 |
| Distance from 52-week high | -28.0% | -22.2% | 6th lowest of 21 |
| Revenue growth (TTM) | +7.8% | +6.9% | 11th highest of 21 |
| Operating margin | 2.2% | 6.2% | 7th lowest of 21 |
| Forward P/E | 16.0× | 29.4× | 5th cheapest of 16 |
| ROIC minus cost of capital | -7.0 pp | -3.1 pp | 6th lowest of 20 |
| EV / EBITDA | 26.8× | 10.7× | 3rd most expensive of 14 |
| Net debt / EBITDA | 10.7× | 1.7× | 2nd most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |